NICE terminate review of Avastin/Erbitux regimens due to lack of data

The UK NICE have announced that review of Avastin and Erbitux for the following indications have been terminated due to lack of data provision by their manufacturers:

- bevacizumab in combination with paclitaxel for the first-line treatment of metastatic breast cancer

- bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with inoperable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology)

- cetuximab for the treatment of colorectal cancer following failure of oxaliplatin-containing chemotherapy